“…The progression of lung cancer is accelerated by the proliferation, movement, and diffusion of tumor cells. CXCL5 has also been reported to promote tumor progression in different tumors such as gastric cancer ( 60 ), liver cancer ( 62 ), bladder cancer ( 65 ), prostate cancer ( 68 ), nasopharyngeal carcinoma, intrahepatic cholangiocarcinoma ( 58 ), osteosarcoma ( 64 ), cholangiocarcinoma ( 59 ), papillary thyroid carcinoma ( 69 ), and renal cell carcinoma ( 71 ). Notably, CXCL5 also induces the development, metastasis, and drug resistance of bladder cancer.…”